Lixte Biotechnology (NASDAQ:LIXT) Trading 2.4% Higher – Still a Buy?

Shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) rose 2.4% on Tuesday . The company traded as high as $3.04 and last traded at $2.97. Approximately 31,760 shares traded hands during trading, a decline of 60% from the average daily volume of 79,738 shares. The stock had previously closed at $2.90.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lixte Biotechnology in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Lixte Biotechnology has a consensus rating of “Sell”.

Lixte Biotechnology Stock Performance

The stock has a market capitalization of $22.22 million, a price-to-earnings ratio of -2.52 and a beta of 0.93. The company has a 50 day moving average of $3.49 and a 200 day moving average of $4.12.

Institutional Trading of Lixte Biotechnology

Several large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its holdings in shares of Lixte Biotechnology by 47.0% during the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock worth $422,000 after acquiring an additional 34,350 shares during the period. Federation des caisses Desjardins du Quebec boosted its holdings in Lixte Biotechnology by 83.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after purchasing an additional 42,530 shares during the last quarter. DRW Securities LLC grew its stake in shares of Lixte Biotechnology by 11.6% in the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after buying an additional 5,645 shares during the period. Geode Capital Management LLC increased its holdings in shares of Lixte Biotechnology by 25.9% during the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after buying an additional 10,722 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Lixte Biotechnology during the 4th quarter valued at approximately $57,000. 5.10% of the stock is currently owned by hedge funds and other institutional investors.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.